L. Broussard, Biological Agents: Weapons of Warfare and Bioterrorism, Molecular Diagnosis, vol.6, issue.4, pp.323-333, 2001.
DOI : 10.2165/00066982-200106040-00013

W. Liu, V. Montana, E. Chapman, U. Mohideen, and V. Parpura, Botulinum toxin type B micromechanosensor, Proceedings of the National Academy of Sciences, vol.14, issue.2, pp.13621-13625, 2003.
DOI : 10.1016/0006-8993(85)90806-6

URL : http://www.pnas.org/content/100/23/13621.full.pdf

D. Franz, L. Pitt, J. Clayton, M. Hanes, and K. Rose, Efficacy of prophylactic and therapeutic administration of antitoxin for inhalation botulism Botulinum and Tetanus Neurotoxins: Neurotransmission and Biomedical Aspects, pp.473-476, 1993.

M. Wheeler, Production of Monovalent botulinus antitoxic serum types A and B, The Journal of Immunology, vol.8, pp.501-505, 1923.

R. Jones, T. Alsop, R. Hull, R. Tierney, and P. Rigsby, Botulinum type A toxin neutralisation by specific IgG and its fragments: A comparison of mouse systemic toxicity and local flaccid paralysis assays, Toxicon, vol.48, issue.3, pp.246-254, 2006.
DOI : 10.1016/j.toxicon.2006.05.007

D. Pless, E. Torres, E. Reinke, and S. Bavari, High-Affinity, Protective Antibodies to the Binding Domain of Botulinum Neurotoxin Type A, Infection and Immunity, vol.69, issue.1, pp.570-574, 2001.
DOI : 10.1128/IAI.69.1.570-574.2001

H. Wu, C. Yen, Y. Huang, and L. Tarn, Characterization of Neutralizing Antibodies and Identification of Neutralizing Epitope Mimics on the Clostridium botulinum Neurotoxin Type A, Applied and Environmental Microbiology, vol.67, issue.7, pp.3201-3207, 2001.
DOI : 10.1128/AEM.67.7.3201-3207.2001

Y. Torii, Y. Tokumaru, S. Kawaguchi, N. Izumi, and S. Maruyama, Production and immunogenic efficacy of botulinum tetravalent (A, B, E, F) toxoid, Vaccine, vol.20, issue.19-20, pp.2556-2561, 2002.
DOI : 10.1016/S0264-410X(02)00157-3

R. Black and R. Gunn, Hypersensitivity reactions associated with botulinal antitoxin, The American Journal of Medicine, vol.69, issue.4, pp.567-570, 1980.
DOI : 10.1016/0002-9343(80)90469-6

P. Amersdorfer, C. Wong, S. Chen, T. Smith, and S. Deshpande, Molecular characterization of murine humoral immune response to botulinum neurotoxin type A binding domain as assessed by using phage antibody libraries, Infection and Immunity, vol.65, pp.3743-3752, 1997.

A. Nowakowski, C. Wang, D. Powers, P. Amersdorfer, and T. Smith, Potent neutralization of botulinum neurotoxin by recombinant oligoclonal antibody, Proceedings of the National Academy of Sciences, vol.287, issue.5458, pp.11346-11350, 2002.
DOI : 10.1126/science.287.5458.1664

URL : http://www.pnas.org/content/99/17/11346.full.pdf

T. Smith, B. Lloyd, N. Spicer, and E. Haber, Immunogenicity and Kinetics of Distribution and Elimination of Sheep Digoxin-Specific Igg and Fab Fragments in the Rabbit and Baboon, Clinical and Experimental Immunology, vol.36, pp.384-396, 1979.

C. Mayers, S. Veall, R. Bedford, and J. Holley, , and Fab Botulinum Antitoxins in Mice, Immunopharmacology and Immunotoxicology, vol.150, issue.3, pp.397-408, 2003.
DOI : 10.1093/infdis/150.3.407

I. Koumenis, Z. Shahrokh, S. Leong, V. Hsei, and L. Deforge, Modulating pharmacokinetics of an anti-interleukin-8 F(ab???)2 by amine-specific PEGylation with preserved bioactivity, International Journal of Pharmaceutics, vol.198, issue.1, pp.83-95, 2000.
DOI : 10.1016/S0378-5173(99)00458-5

DOI : 10.1006/cyto.2001.0936

A. Chapman, P. Antoniw, M. Spitali, S. West, and S. Stephens, Therapeutic antibody fragments with prolonged in vivo half-lives, Nature Biotechnology, vol.217, issue.8, pp.780-783, 1999.
DOI : 10.1016/S0022-1759(98)00061-1

A. Chapman, PEGylated antibodies and antibody fragments for improved therapy: a review, Advanced Drug Delivery Reviews, vol.54, issue.4, pp.531-545, 2002.
DOI : 10.1016/S0169-409X(02)00026-1

C. Shone and H. Tranter, Growth of Clostridia and Preparation of Their Neurotoxins, pp.143-160, 1995.
DOI : 10.1007/978-3-642-85173-5_7

M. Tavallaie, A. Chenal, D. Gillet, Y. Pereira, and M. Manich, Interaction between the two subdomains of the C-terminal part of the botulinum neurotoxin A is essential for the generation of protective antibodies, FEBS Letters, vol.23, issue.1-3, pp.299-306, 2004.
DOI : 10.1023/B:JOPC.0000016257.91979.06

H. Volland, P. Lamourette, M. Nevers, C. Mazuet, and E. Ezan, A sensitive sandwich enzyme immunoassay for free or complexed Clostridium botulinum neurotoxin type A, Journal of Immunological Methods, vol.330, issue.1-2, pp.120-129, 2008.
DOI : 10.1016/j.jim.2007.11.006

E. Lamoyi and A. Nisonoff, Preparation of F(ab???)2 fragments from mouse IgG of various subclasses, Journal of Immunological Methods, vol.56, issue.2, pp.235-243, 1983.
DOI : 10.1016/0022-1759(83)90415-5

C. Hatheway and C. Dang, Immunogenicity of neurotoxins of Clostridium Botulinum in therapy with botulinum toxin, pp.93-107, 1994.

K. Hill, T. Smith, C. Helma, L. Ticknor, and B. Foley, Genetic Diversity among Botulinum Neurotoxin-Producing Clostridial Strains, Journal of Bacteriology, vol.189, issue.3, pp.818-832, 2007.
DOI : 10.1128/JB.01180-06

URL : http://jb.asm.org/content/189/3/818.full.pdf

A. Carter, C. Paul, D. Mason, S. Twine, and M. Alston, Independent evolution of neurotoxin and flagellar genetic loci in proteolytic Clostridium botulinum, BMC Genomics, vol.10, issue.1, 2009.
DOI : 10.1186/1471-2164-10-115

URL : https://bmcgenomics.biomedcentral.com/track/pdf/10.1186/1471-2164-10-115?site=bmcgenomics.biomedcentral.com

N. Dover, J. Barash, and S. Arnon, Novel Clostridium botulinum Toxin Gene Arrangement with Subtype A5 and Partial Subtype B3 Botulinum Neurotoxin Genes, Journal of Clinical Microbiology, vol.47, issue.7, pp.2349-2350, 2009.
DOI : 10.1128/JCM.00799-09

URL : http://jcm.asm.org/content/47/7/2349.full.pdf

T. Smith, J. Lou, I. Geren, C. Forsyth, and R. Tsai, Sequence Variation within Botulinum Neurotoxin Serotypes Impacts Antibody Binding and Neutralization, Infection and Immunity, vol.73, issue.9, pp.5450-5457, 2005.
DOI : 10.1128/IAI.73.9.5450-5457.2005

URL : http://iai.asm.org/content/73/9/5450.full.pdf

L. Smith, Development of recombinant vaccines for botulinum neurotoxin, Toxicon, vol.36, issue.11, pp.1539-1548, 1998.
DOI : 10.1016/S0041-0101(98)00146-9

M. Clayton, J. Clayton, D. Brown, and J. Middlebrook, Protective Vaccination with A Recombinant Fragment of Clostridium-Botulinum Neurotoxin Serotype A Expressed from A Synthetic Gene in Escherichia-Coli, Infection and Immunity, vol.63, pp.2738-2742, 1995.

R. Sheridan, S. Deshpande, P. Amersdorfer, J. Marks, and T. Smith, Anomalous enhancement of botulinum toxin type A neurotoxicity in the presence of antitoxin, Toxicon, vol.39, issue.5, pp.651-657, 2001.
DOI : 10.1016/S0041-0101(00)00189-6

S. Arnon, Clinical trial of human botulism immune globulin Botulinum and Tetanus Neurotoxins: Neurotransmission and Biomedical Aspects, pp.477-482, 1993.
DOI : 10.1007/978-1-4757-9542-4_53

J. Arndt, M. Jacobson, E. Abola, C. Forsyth, and W. Tepp, A Structural Perspective of the Sequence Variability Within Botulinum Neurotoxin Subtypes A1-A4, Journal of Molecular Biology, vol.362, issue.4, pp.733-742, 2006.
DOI : 10.1016/j.jmb.2006.07.040

M. Knauf, D. Bell, P. Hirtzer, Z. Luo, and J. Young, Relationship of Effective Molecular-Size to Systemic Clearance in Rats of Recombinant Interleukin-2 Chemically Modified with Water-Soluble Polymers, Journal of Biological Chemistry, vol.263, pp.15064-15070, 1988.

E. Lobo, R. Hansen, and J. Balthasar, Antibody Pharmacokinetics and Pharmacodynamics, Journal of Pharmaceutical Sciences, vol.93, issue.11, pp.2645-2668, 2004.
DOI : 10.1002/jps.20178

S. Batra, M. Jain, U. Wittel, S. Chauhan, and D. Colcher, Pharmacokinetics and biodistribution of genetically engineered antibodies, Current Opinion in Biotechnology, vol.13, issue.6, pp.603-608, 2002.
DOI : 10.1016/S0958-1669(02)00352-X